Prosecution Insights
Last updated: April 19, 2026

Allogene Therapeutics, Inc.

5 pending office actions • 1 client

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Client Portfolio (1 client)

Client (Assignee)Pending OAs
Allogene Therapeutics, Inc. 5

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
18450554 METHOD FOR INHIBITING ADVENTITIOUS VIRAL INFECTION Allogene Therapeutics, Inc. PENNINGTON, HALLIE NICOLE 1671 Non-Final OA Aug 16, 2023
18365014 CHIMERIC CYTOKINE RECEPTORS BEARING A PD-1 ECTODOMAIN Allogene Therapeutics, Inc. SANG, HONG 1646 Non-Final OA Aug 03, 2023
17550311 METHODS AND REAGENTS FOR CHARACTERIZING CAR T CELLS FOR THERAPIES Allogene Therapeutics, Inc. SPENCE, JENNIFER SUZANNE 1633 Final Rejection Dec 14, 2021
16826102 METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY Allogene Therapeutics, Inc. DHAR, MATASHA 1632 Non-Final OA Mar 20, 2020
16695894 CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF USE THEREOF Allogene Therapeutics, Inc. HALVORSON, MARK 1646 Non-Final OA Nov 26, 2019

Managing Allogene Therapeutics, Inc.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month